Detailed Information on Publication Record
2014
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
RAZAVI, H., I. WAKED, C. SARRAZIN, R. P. MYERS, R. IDILMAN et. al.Basic information
Original name
The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
Authors
RAZAVI, H. (840 United States of America), I. WAKED (818 Egypt), C. SARRAZIN (276 Germany), R. P. MYERS (124 Canada), R. IDILMAN (792 Turkey), F. CALINAS (620 Portugal), W. VOGEL (40 Austria), M. C. Mendes CORREA (76 Brazil), C. HÉZODE (250 France), P. LÁZARO (724 Spain), U. AKARCA (792 Turkey), S. ALEMAN (752 Sweden), I. BALIK (792 Turkey), T. BERG (276 Germany), F. BIHL (756 Switzerland), M. BILODEAU (124 Canada), A. J. BLASCO (724 Spain), C. E. Brandão MELLO (76 Brazil), P. BRUGGMANN (756 Switzerland), M. BUTI (724 Spain), J. L. CALLEJA (724 Spain), H. CHEINQUER (76 Brazil), P. B. CHRISTENSEN (208 Denmark), M. CLAUSEN (208 Denmark), H. S. M. COELHO (76 Brazil), M. E. CRAMP (826 United Kingdom of Great Britain and Northern Ireland), G. J. DORE (36 Australia), W. DOSS (818 Egypt), A. S. DUBERG (752 Sweden), M. H. EL-SAYED (818 Egypt), G. ERGÖR (792 Turkey), G. ESMAT (818 Egypt), K. FALCONER (752 Sweden), J. FÉLIX (620 Portugal), M. L. G. FERRAZ (76 Brazil), P. R. FERREIRA (76 Brazil), S. FRANKOVA (203 Czech Republic), J. GARCÍA-SAMANIEGO (724 Spain), J. GERSTOFT (208 Denmark), J. A. GIRIA (620 Portugal), F. L. Jr. GONÇALES (76 Brazil), E. GOWER (840 United States of America), M. GSCHWANTLER (40 Austria), M. Guimarães PESSÔA (76 Brazil), S. J. HINDMAN (840 United States of America), H. HOFER (40 Austria), Petr HUSA (203 Czech Republic, guarantor, belonging to the institution), M. KÅBERG (752 Sweden), K. D. E. KAITA (124 Canada), A. KAUTZ (56 Belgium), S. KAYMAKOGLU (792 Turkey), M. KRAJDEN (124 Canada), H. KRARUP (208 Denmark), W. LALEMAN (56 Belgium), D. LAVANCHY (756 Switzerland), R. T. MARINHO (620 Portugal), P. MAROTTA (124 Canada), S. MAUSS (276 Germany), C. MORENO (56 Belgium), K. MURPHY (840 United States of America), F. NEGRO (756 Switzerland), V. NEMECEK (203 Czech Republic), N. ÖRMECI (792 Turkey), A. L. H. ØVREHUS (208 Denmark), J. PARKES (826 United Kingdom of Great Britain and Northern Ireland), K. PASINI (840 United States of America), K. M. PELTEKIAN (124 Canada), A. RAMJI (124 Canada), N. REIS (620 Portugal), S. K. ROBERTS (36 Australia), W. M. ROSENBERG (826 United Kingdom of Great Britain and Northern Ireland), F. ROUDOT-THORAVAL (250 France), S. D. RYDER (826 United Kingdom of Great Britain and Northern Ireland), R. SARMENTO-CASTRO (620 Portugal), D. SEMELA (756 Switzerland), M. SHERMAN (124 Canada), G. E. SHIHA (818 Egypt), W. SIEVERT (36 Australia), J. SPERL (203 Czech Republic), P. STÄRKEL (56 Belgium), R. E. STAUBER (40 Austria), A. J. THOMPSON (36 Australia), P. URBANEK (203 Czech Republic), P. Van DAMME (56 Belgium), I. van THIEL (276 Germany), H. Van VLIERBERGHE (56 Belgium), D. VANDIJCK (56 Belgium), H. WEDEMEYER (276 Germany), N. WEIS (208 Denmark), J. WIEGAND (792 Turkey), A. YOSRY (818 Egypt), A. ZEKRY (36 Australia), M. CORNBERG (276 Germany), B. MÜLLHAUPT (756 Switzerland) and C. ESTES (840 United States of America)
Edition
JOURNAL OF VIRAL HEPATITIS, HOBOKEN, WILEY-BLACKWELL, 2014, 1352-0504
Other information
Language
English
Type of outcome
Článek v odborném periodiku
Field of Study
30300 3.3 Health sciences
Country of publisher
United States of America
Confidentiality degree
není předmětem státního či obchodního tajemství
Impact factor
Impact factor: 3.909
RIV identification code
RIV/00216224:14110/14:00075468
Organization unit
Faculty of Medicine
UT WoS
000333893200003
Keywords in English
HCV; diagnosis; treatment; hepatitis C; prevalence; epidemiology; disease burden; mortality; incidence
Tags
Tags
International impact, Reviewed
Změněno: 13/5/2014 16:58, Ing. Mgr. Věra Pospíšilíková
Abstract
V originále
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.